Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-11-13 Director's Dealing
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-11-13 English
FORM 4
Director's Dealing
2017-11-09 English
FORM 4
Director's Dealing
2017-11-07 English
Interim / Quarterly Report 2017
Interim / Quarterly Report 9M 2017
2017-11-03 English
Earnings Release 2017
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 2, 2017, reporting the results of operations and financial condition for the period ended September 30, 2017. It includes a press release as an exhibit announcing financial results. The text indicates this is an initial announcement of quarterly/periodical financial results, typical of an Earnings Release. The document length is under 5,000 characters and primarily contains the announcement and a press release, not the full financial statements or detailed analysis. Therefore, it fits the definition of an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2017-11-02 English
M&A Activity 2017
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events. The content describes the completion of an acquisition of assets related to a vaccine business, including payment details and agreements. It references the acquisition completion date and related agreements but does not contain detailed financial statements or comprehensive financial analysis. The document is an announcement of a significant corporate transaction (acquisition) rather than a full merger proxy statement or tender offer filing. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length (7475 characters) and detailed description support this classification with high confidence.
2017-10-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.